In this sense, the detection in ctDNA of two CpG sites differentially methylated at the promoter of the peroxisome proliferator-activated receptor γ gene (PPARγ) has been proposed to stratify liver fibrosis in patients with NAFLD [99]. This evidence concerns the gene PPARG and metabolic dysfunction-associated steatotic liver disease.